開会前ワークショップ - 10月21日 - 日本標準時(GMT+09:00)
開会前ワークショップ - 10月21日 - 日本標準時(GMT+09:00)
受付
モーニングワークショップ:CDMO管理の概要
Add-on this optional pre-conference workshop to your main conference registration package and gain a comprehensive overview of CDMO Management in an easy-to-follow classroom setting to help you prepare for the main conference program.
Understanding the Japanese CDMO Landscape
- Introduction to Japanese Business Culture
- Historical Overview and Current Trends in the CDMO Industry
- Interactive Discussion
- Participants share their current understanding and experiences with Japanese CDMOs.
- Group activity: Identify key cultural differences that could impact business relationships.
Strategic Partnering with Japanese CDMOs
- Key Players and Capabilities in the Japanese CDMO Market
- CDMO Selection Frameworks
- Case Study, groups and presentations: CDMO Selection
Negotiation and Collaboration
- Collaboration Models
- Case Study, groups and presentations: Negotiation and Collaboration
- Small Group Discussions: Aligning Expectations
Execution, Relationship Maintenance, and Conflict Resolution
- Executing a Seamless Tech Transfer
- Maintaining Relationships and Conflict Resolution
- Interactive Session: Win-Win Thinking in Practice
- Final Q&A and Wrap-Up
- Workshop registration begins at 7:30 am
ワークショップ受付開始時間:午前7:30 - Morning Break: -10:30-10:50
休憩時間:午前10:30〜10:50
- Stefan Sandstrom - CEO, Biosector Ltd., Japan
昼食会:本会議+半日間ワークショップ(2回分)のパスホルダー向け
アフタヌーンワークショップ:細胞・遺伝子製造の概要
Add-on this optional pre-conference workshop to your main conference registration package and gain a comprehensive overview of Cell and Gene Therapy Manufacturing in an easy-to-follow classroom setting to help you prepare for the main conference program.
- Workshop registration begins at 12:30 pm
ワークショップ受付開始時間:午後12:30 - Afternoon Break: ~ 3:30-3:50pm
休憩時間:午後3:30〜3:50
How does Cell and Gene Therapy Manufacturing Differ from other Biological Products?
- The manufacturing diversity of cell and gene products, examples.
- Limitations when controlling adventitious agents
- Complex starting and raw materials
- Batch size, and stability
- Christopher Bravery - Consulting Regulatory Scientist, Consulting on Advanced Biologicals, UK
* 不測の事態により、事前の予告なしにプログラムが変更される場合があります。